CN104013926A - Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver - Google Patents
Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver Download PDFInfo
- Publication number
- CN104013926A CN104013926A CN201410303935.7A CN201410303935A CN104013926A CN 104013926 A CN104013926 A CN 104013926A CN 201410303935 A CN201410303935 A CN 201410303935A CN 104013926 A CN104013926 A CN 104013926A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicines and particularly relates to a traditional Chinese medicine composition and an application of the traditional Chinese medicine composition as a medicine for treating fatty liver. The traditional Chinese medicine composition for treating or preventing fatty liver comprises the following components in parts by weight: 5-15 parts of radix curcumae, 3-9 parts of poria cocos, 5-15 parts of pericarpium citri reticulatae, 5-15 parts of ligusticum wallichii, 18-23 parts of pinellia ternate, 18-23 parts of hawthorn, 5-15 parts of radix bupleuri, 15 parts of turmeric, 20-50 parts of semen cassiae, 2-7 parts of radix paeoniae alba, 3-9 parts of salviae miltiorrhizae and 5-15 parts of polygonum cuspidatum. The traditional Chinese medicine composition has a good curative effect on treatment of fatty liver and has a remarkable clinical application value.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Chinese medicine composition and as the application of fatty liver medicine.
Background technology
According to the pathogenic factor of fatty liver, fatty liver is divided into alcoholic fatty liver and non-alcohol fatty liver (NAFLD), the latter is one of clinical common hepatopathy, and its pathogenesis is still not clear at present, has research to think that insulin resistant (IR) is one of Important cause of disease causing NAFLD.Along with the change of life style and diet structure, the sickness rate of NAFLD obviously increases.Nearly ten years, non-alcohol fatty liver sickness rate in the Asian-Pacific area increases rapidly.The adult NAFLD prevalence of China areas of well-being approaches (12%-24%) with Japan, Korea S, and has replaced the primary cause of disease that Chronic Hepatitis B Virus infection (prevalence <7.0%) becomes chronic hepatopathy.
Fatty liver is often out in the cold in early days in daily life, often delays to abnormal liver function, hepatic fibrosis, even develops into liver cirrhosis.With regard to medical angle, say, due to the impact of the factors such as people's living habit, dietary structure change, in current China, pathogenesis of fatty liver rate is the situation increasing sharply.According to related data, show, mostly fatty liver is what diabetes, obesity, hepatitis virus or other pathogenic infection etc. caused.Although have the Western medicine of much treating for fatty liver on market now, because these blood fat reducing Western medicine mostly have potential hepatotoxicity, and action target spot is single, therefore can not obtain the effect of satisfied treatment.Researching and developing a kind of effective medicine to fatty liver is of great practical significance.
In conjunction with modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened to the preparation that extraction and/or compatibility make, its side effect is little, safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
For current fatty liver, there is no very effective Drug therapy, the invention provides a kind of Chinese medicine composition for the treatment of solid tumor, this Chinese medicine composition has good curative effect aspect treatment fatty liver.Chinese medicine composition of the present invention, according to components by weight percent meter, comprise following component: Radix Curcumae 5-15 part, Poria 3-9 part, Pericarpium Citri Reticulatae 5-15 part, Rhizoma Chuanxiong 5-15 part, Rhizoma Pinelliae 18-23 part, Fructus Crataegi 18-23 part, Radix Bupleuri 5-15 part, 15 parts, Rhizoma Curcumae Longae, Semen Cassiae 20-50 part, Radix Paeoniae Alba 2-7 part, Radix Salviae Miltiorrhizae 3-9 part, Rhizoma Polygoni Cuspidati 5-15 part.
In pharmaceutical composition of the present invention, Radix Curcumae regulating qi to disperse stagnation, heart fire-clearing upset-relieving, promoting the function of the gallbladder to alleviate jaundice, this product pungent drugs can disperse and bitter drugs can descend, fragrance should reach, and can enter edema caused by disorder of QI resolving depression and enter again blood system cooling blood and dissolving stasis, are the gas medicine in blood.
Poria is the dry sclerotia of On Polyporaceae Poria.Another name: lie prostrate tire, Poria, Fu rabbit, loose potato, Masson Pine potato, Song Ling in Fu Tu, Poria, Fu Ling, Fu Ling, volt Tu, loose fat, deep red morning.Be used as medicine there is promoting diuresis to eliminate damp pathogen, the function of strengthening the spleen stomach function regulating, mind tranquilizing and the heart calming.Poria energy enhancing human body immunity function, pachyman has obvious antitumor and protects the liver dirty effect.As cold-damp person relatively, can with the compatibility such as Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae; Belong to deficiency and coldness person, also can join Radix Aconiti Lateralis Preparata, the Rhizoma Atractylodis Macrocephalae is equal to use.Be partial to damp and hot person, can with the compatibilities such as Polyporus, Rhizoma Alismatis; The person that belongs to deficiency of spleen-QI, can with the compatibilities such as Radix Codonopsis, Radix Astragali, the Rhizoma Atractylodis Macrocephalae; For insufficiency of the spleen can not transmitting and distributing the fluids, stop the disease of the raw phlegm retention of dimerization, the available Rhizoma Pinelliae, the same use of Pericarpium Citri Reticulatae, also can join Ramulus Cinnamomi, the Rhizoma Atractylodis Macrocephalae with using.Control phlegm-damp and enter network, aching shoulder and back, can join the Rhizoma Pinelliae, Fructus Aurantii with using.For diseases such as irritability, cardiopalmus, insomnia, the compatibilities such as normal and Radix Ginseng, Radix Polygalae, Semen Ziziphi Spinosae.For having loose bowels due to insufficiency of the spleen dysfunction of the spleen in transportation and transformation, leukorrhagia, application Poria has the effect of giving consideration to both the incidental and fundamental, the compatibilities such as normal and Radix Codonopsis, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae.Can be used as tonifying the lung spleen, control the adjuvant of the deficiency of vital energy.
Pericarpium Citri Reticulatae is warm in nature, bitter in the mouth, pungent.Function cures mainly, regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm.For fullness in the epigastrium and chest, lack of appetite and vomiting, cough ant phlegm.
The pungent temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go loose, the up top, mountain peak that reaches; Enter again blood system, the descending sea of blood that reaches.Blood circulation promoting and blood stasis dispelling effect is extensive, the various diseases of suitable stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia.
The Rhizoma Pinelliae is the dry tuber of aroid Rhizoma Pinelliae Pinellia ternata (Thunb.) Breit..Temperature; Pungent; Return spleen, stomach, lung meridian; Poison.Drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass.For abundant expectoration cough with asthma, phlegm retention vertigo and palpitation, dizziness due to wind-phlegm, syncope due to accumulation of phlegm headache, vomiting regurgitation, breast gastral cavity painful abdominal mass is vexed, globus hystericus; Raw with external treatment carbuncle sucutaneous nodule.
Fructus Crataegi does medicinal with fruit, slightly warm in nature, and sour in the mouth is sweet, enters spleen, stomach, Liver Channel, has the function of promoting digestion and invigorating the stomach, activating blood circulation to dissipate blood stasis, convergence dysentery relieving.To the long-pending phlegm retention of meat, feeling of fullness acid regurgitation, dysentery hemorrhoidal hamorrhage, lumbago hernia, puerperal after-pains, lochiorrhea, children's's breast food stagnate etc., all effective in cure.< < herbal classic > > cloud: sour in the mouth, air cooling, so see its can help digestion long-pending, clots absorbing blood, gas is non-cold.Having stagnates becomes dysentery, prolonged lochia, and holding in lunar part is after-pains.It is stagnant that Fructus Crataegi can enter taste removing food stagnancy, loose stagnated blood.
Radix Bupleuri cold nature, bitter in the mouth, pungent, return Liver Channel, gallbladder meridian, has expelling pathogenic factors from the exterior and expel the heat-evil, dispersing the stagnated live-QI to relieve the stagnation of QI, the effect of elevate a turnable ladder yang-energy.< < Bencao Jingshu > >: Radix Bupleuri is shaoyang channel medicine administered to bring out the cold.Stagnation of QI in main trusted subordinate's the intestines and stomach, diet gathers, and cold and heat pathogen, pushes away Chen Zhixin, and except dysphoria with smothery sensation person under the typhoid fever heart, foot-shaoyang gallbladder is also.Gallbladder is peace and quiet mansion, without going out without entering, khan not, emetic should not be given, purgative being prohibited, it is through at half exterior and half interior, therefore method from conciliating, the genus of Herba Sidae Rhombifoliae soup is also.Its property rises and falls apart, and occupies sun, therefore can reach the loose heresy of table also.Pathogens agglomerating is dysphoria with smothery sensation under the heart, and evil loose dysphoria with smothery sensation is explained by oneself.Yang-energy sink, and for diet gathers, sun rises that clearing heat in QI system is up, QI of the spleen and stomach Hang Yang road, and diet gathers from dissipation.All expectorant accumulation of heats are real, evil contrary in the heart, faint breath person between the five internal organs, and the evil disease of viscera connecting with this channel of few YANG excess heat is also.Radix Bupleuri is bitter flat and be slightly cold, can heat extraction eliminating stagnation and induce sweat, therefore can above all diseases.
The Radix Paeoniae Alba enters liver, spleen channel, has nourishing blood to suppress the hyperactive liver, slow middle pain relieving, and yin fluid astringing is received the effect of antiperspirant.Cure mainly the breast abdomen pain over the hypochondriac region, dysentery stomachache, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, is with inferior disease.
Radix Salviae Miltiorrhizae has another name called Radix Salviae Miltiorrhizae, Radix Salviae Miltiorrhizae, Arisaema balansae Engl. etc.For dicotyledon Labiatae, dry root and rhizome.Main product in Anhui, the ground such as Henan, Shaanxi.Effect: promoting blood flow to regulate menstruation, stasis-dispelling and pain-killing, removing heat from blood eliminating carbuncle, the relieving restlessness that clears away heart-fire, nourishing blood to tranquillize the mind.Rhizoma Polygoni Cuspidati promoting the function of the gallbladder to alleviate jaundice, heat-clearing and toxic substances removing, blood circulation promoting and blood stasis dispelling, expelling phlegm for arresting cough, this product bitter cold, kind let out the middle burnt stasis of blood stagnant, rush down dampness-heat in the liver and gallbladder, be again that wet good medicine is mended in heat clearing away.
As a kind of embodiment preferred for this invention, the raw material by following weight portion in above-mentioned Chinese medicine composition makes: 10 parts of Radix Curcumaes, 6 parts, Poria, 10 parts of Pericarpium Citri Reticulataes, 10 parts of Rhizoma Chuanxiongs, 20 parts of the Rhizoma Pinelliaes, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts, Rhizoma Curcumae Longae, 30 parts of Semen Cassiaes, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Polygoni Cuspidati.The therapeutic effect of Chinese medicine composition to fatty liver can be further strengthened, and the drug toxicity of medicine to body can be reduced.
The method of preparing Chinese medicine composition of the present invention is as follows: get each medical material of above-mentioned components by weight percent, add the water of 5-15 times of medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filters, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, and this relative density is the testing result under 60 degrees Celsius, and adding ethanol is 60-90%(v/v to containing alcohol amount), standing 24 hours, get supernatant, reclaim ethanol to concentrated, obtain.The above-mentioned Chinese medicine composition of the present invention can further be prepared into conventional clinically pharmaceutical preparation, is preferably mixture, tablet, capsule.
The present invention also discloses a kind of purposes of above-mentioned Chinese medicine composition, i.e. the purposes of above-mentioned Chinese medicine composition in preparation treatment or prevention fatty liver medicine.The present invention tests the treatment of Making Rat Models of Nonalcoholic by investigating Chinese medicine composition of the present invention, find that Chinese medicine composition provided by the invention can obviously reduce AST and the ALT of Rats with Fatty Liver model, TG, TC and the LDL-C of fatty rat model can be significantly reduced, and the liver index of rat model can be significantly reduced.This acts on comprehensively while showing Chinese medicine composition of the present invention to treatment or prevention fatty liver disease, has obvious synergism, has obtained unforeseeable curative effect of medication.Its therapeutic effect to fatty liver is better than existing medicine silibinin.
In a word, the present invention compared with prior art, has the activity of fine treatment fatty liver, and can the present invention be pure Chinese medicinal preparation, to human body particularly to liver avirulence.When the present invention uses as fatty liver medicine, drug effect is comprehensive, in dispersing the stagnated live-QI to relieve the stagnation of QI, spleen invigorating food stagnation removing, can also obtain the effect of activating blood circulation to dissipate blood stasis, dispelling phlegm and eliminating dampness, and sb.'s illness took a favorable turn can to make rapidly Patients with Fatty Liver; And Chinese medicine composition preparation of the present invention is simple, and substantially nontoxic, raw material is easy to get, and is suitable for popular use, has good application prospect.
The specific embodiment
By the specific embodiment, further describe the present invention below, but the present invention is not limited only to following examples.Within the scope of the invention or within not departing from the scope of content of the present invention and spirit, Chinese medicine composition of the present invention is suitably improved, replaces the component that effect is identical, within will become apparent to those skilled in the art that they are all deemed to be included in scope of the present invention.
first, the preparation of Chinese medicine composition of the present invention
embodiment 1 Chinese medicinal composition capsules of the present invention
Prescription: 10 parts of Radix Curcumaes, 6 parts, Poria, 10 parts of Pericarpium Citri Reticulataes, 10 parts of Rhizoma Chuanxiongs, 20 parts of the Rhizoma Pinelliaes, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts, Rhizoma Curcumae Longae, 30 parts of Semen Cassiaes, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Polygoni Cuspidati.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 8 times of medical material gross weight, soak 45 minutes, decoct 4 times, each 1.5 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.2, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 90%(v/v to containing alcohol amount), standing 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulates, encapsulated and get final product.
embodiment 2 Chinese medicine composition mixture of the present invention
Prescription: 10 parts of Radix Curcumaes, 6 parts, Poria, 10 parts of Pericarpium Citri Reticulataes, 10 parts of Rhizoma Chuanxiongs, 20 parts of the Rhizoma Pinelliaes, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts, Rhizoma Curcumae Longae, 30 parts of Semen Cassiaes, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Polygoni Cuspidati.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 5 times of medical material gross weight, soak 30 minutes, decoct 2 times, each 2 hours, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.1, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 75%(v/v to containing alcohol amount), standing 24 hours, get supernatant, recovery ethanol is concentrated, adds water to 1000ml, stirs evenly, subpackage, flowing steam sterilization 35min, obtains mixture.
embodiment 3 Chinese medicine composition tablet of the present invention
Prescription: 10 parts of Radix Curcumaes, 6 parts, Poria, 10 parts of Pericarpium Citri Reticulataes, 10 parts of Rhizoma Chuanxiongs, 20 parts of the Rhizoma Pinelliaes, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts, Rhizoma Curcumae Longae, 30 parts of Semen Cassiaes, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Polygoni Cuspidati.
Preparation method: get each medical material of above-mentioned components by weight percent, add the water of 10 times of medical material gross weight, soak 60 minutes, decoct 1 time, each 1 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.25, and this relative density is the testing result under 60 degrees Celsius, adding ethanol is 80%(v/v to containing alcohol amount), standing 24 hours, get supernatant, reclaim ethanol to concentrated, vacuum drying, granulation, tabletting and get final product.
second portion, the pharmacodynamics of Chinese medicine composition of the present invention is investigated
the treatment of embodiment 4 Chinese medicine composition of the present invention to non-alcoholic fatty liver disease
The preparation of 1 nonalcoholic fatty liver model
SD rat, male, body weight 220 ± 20g, adopts the method modeling of the high lipoprotein emulsion associating of gavage lumbar injection tetracycline.Except Normal group, all the other each groups give lumbar injection tetracycline 150mg/kg on the 1st day in modeling, after every 6d lumbar injection tetracycline 110mg/kg1 time, totally 6 times.Except normal group, every group in the high lipoprotein emulsion of every morning 9:00 gavage, dosage 10mlkg
-1d
-1.High lipoprotein emulsion formula: Adeps Sus domestica 20g, cholesterol 10g, fructose 5g, sucrose 5g, cholate 1g, sodium glutamate 1g, propylene glycol 15ml, a little POLYSORBATE 80, distilled water is settled to 100ml.Gavage continues 8W to high fat breast.
2 grouping and administrations
Rat model adaptability was raised after 1 week, was divided at random normal group, model group and administration group, and specifically grouping situation sees the following form, 12 every group.Every afternoon is gavage medicine during 14:00, and dosage is as follows:
Normal group: gavage gives the distilled water of same volume;
Model control group: gavage gives the distilled water of same volume;
Silibinin group: gavage gives 25mg/(kg.d) silibinin;
Low dose group: gavage gives the embodiment of the present invention 1 prepared Chinese medicine composition mixture, crude drug dosage 0.1 g/(kg.d);
Middle dosage group: gavage gives the embodiment of the present invention 1 prepared Chinese medicine composition mixture, crude drug dosage 1 g/(kg.d);
High dose group: gavage gives the embodiment of the present invention 1 prepared Chinese medicine composition mixture, crude drug dosage 10 g/(kg.d).
3 detect index
After last administration, pentobarbital sodium anesthetized rat, dissects, and abdomen cardinal vein is got hematometry biochemical indicator, gets liver and weighs.
3.1. liver function
Result of the test shows (referring to table 1), Models of Fatty Liver group rat blood serum ALT, AST content are compared with normal group significantly and are raise, the rat blood serum ALT of each administration group, AST content are compared obvious decline with model group, especially, each dosage group of compound recipe is compared with model group has utmost point significant difference, compared utmost point significant difference with silibinin group, each Chinese medicine of this explanation Chinese medicine composition of the present invention has been obtained synergitic effect on to the prevention of rat fat liver or treatment.
The impact of table 1 Chinese medicine composition of the present invention on rat model liver function
With model group comparison,
* p < 0.05; With model group comparison,
* p < 0.01;
With the comparison of silibinin group,
#p < 0.05; With the comparison of silibinin group,
##p < 0.01.
3.2 blood fat
Result of the test shows (referring to table 2), the level of T-CHOL, triglyceride, HDL-C and the low-density lipoprotein cholesterol of each dosage group of compound recipe has been compared significant difference or utmost point significant difference with fatty liver model of rats group, compare with silibinin group or low molecular weight heparin group and also there is significant difference or utmost point significant difference (except hdl level), Chinese medicine use in conjunction in this explanation Chinese medicine composition of the present invention, on fatty liver model of rats, on reduction TG, TC and LDL-C, obtained good synergism.
The impact of table 2 Chinese medicine composition of the present invention on rat fat
With model group comparison,
* p < 0.05; With model group comparison,
* p < 0.01;
With the comparison of silibinin group,
#p < 0.05; With the comparison of silibinin group,
##p < 0.01.
3.3. liver index
Result of the test shows (referring to table 3), Models of Fatty Liver group rats'liver index has been compared utmost point significant difference with normal group, the liver index of the rat of each administration group has been compared utmost point significant difference with model group, especially, each dosage group of compound recipe has been compared significant difference or utmost point significant difference with pyrrole group or Low molecular heparin group, each Chinese medicine of this explanation Chinese medicine composition of the present invention, on fatty liver model of rats, has been obtained good synergism in this index of reduction liver index.
The impact of table 3 Chinese medicine composition of the present invention on Rats Organs and Tissues index
With normal group comparison,
$ p < 0.05; With normal group comparison,
$$ p < 0.01;
With model group comparison,
* p < 0.05; With model group comparison,
* p < 0.01;
With the comparison of silibinin group,
#p < 0.05; With the comparison of silibinin group,
##p < 0.01.
Claims (5)
1. a Chinese medicine composition, is characterized in that it is made by the raw material of following weight portion: Radix Curcumae 5-15 part, Poria 3-9 part, Pericarpium Citri Reticulatae 5-15 part, Rhizoma Chuanxiong 5-15 part, Rhizoma Pinelliae 18-23 part, Fructus Crataegi 18-23 part, Radix Bupleuri 5-15 part, 15 parts, Rhizoma Curcumae Longae, Semen Cassiae 20-50 part, Radix Paeoniae Alba 2-7 part, Radix Salviae Miltiorrhizae 3-9 part, Rhizoma Polygoni Cuspidati 5-15 part.
2. Chinese medicine composition as claimed in claim 1, is characterized in that: described Chinese medicine composition is made by the raw material of following weight portion: 10 parts of Radix Curcumaes, 6 parts, Poria, 10 parts of Pericarpium Citri Reticulataes, 10 parts of Rhizoma Chuanxiongs, 20 parts of the Rhizoma Pinelliaes, 20 parts of Fructus Crataegis, 10 parts of Radix Bupleuri, 15 parts, Rhizoma Curcumae Longae, 30 parts of Semen Cassiaes, 5 parts of the Radix Paeoniae Albas, 6 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Polygoni Cuspidati.
3. Chinese medicine composition as claimed in claim 1, is characterized in that: described Chinese medicine composition is mixture, tablet or capsule.
4. a method of preparing the Chinese medicine composition as described in as arbitrary in claim 1-3, it is characterized in that it comprises the following steps: get each medical material, the water of 5-15 times that adds medical material gross weight, soak 10-60 minute, decoct 1-4 time, each 1-3 hour, filter, merging filtrate, filtrate decompression is concentrated into the extractum of relative density 1.05-1.25, this relative density is the testing result under 60 degrees Celsius, add ethanol to being 60-90%v/v containing alcohol amount, standing 24 hours, get supernatant, reclaim ethanol to concentrated, obtain.
5. the purposes of the Chinese medicine composition as described in as arbitrary in claim 1-3 in preparation treatment or prevention fatty liver medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410303935.7A CN104013926A (en) | 2014-06-30 | 2014-06-30 | Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410303935.7A CN104013926A (en) | 2014-06-30 | 2014-06-30 | Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104013926A true CN104013926A (en) | 2014-09-03 |
Family
ID=51431107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410303935.7A Pending CN104013926A (en) | 2014-06-30 | 2014-06-30 | Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104013926A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104274610A (en) * | 2014-10-30 | 2015-01-14 | 崔新明 | Traditional Chinese medicine composition for treating fatty liver |
| CN104491094A (en) * | 2014-12-19 | 2015-04-08 | 孙丰卿 | Traditional Chinese medicine composition for treating fatty liver and preparation method of preparation thereof |
| CN104606641A (en) * | 2015-02-06 | 2015-05-13 | 刘延玲 | Traditional Chinese medicine for promoting fat metabolism and preparation method of traditional Chinese medicine |
| CN104888155A (en) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating fatty liver combined hyperlipidemia and preparation method thereof |
| CN105535826A (en) * | 2015-12-29 | 2016-05-04 | 上海珍岛信息技术有限公司 | Pharmaceutical composition for treating cat fatty liver and preparation method thereof |
| CN105797010A (en) * | 2014-12-29 | 2016-07-27 | 伊启棒（天津）科技发展有限公司 | Composition for improving fatty liver |
| CN113349311A (en) * | 2021-06-28 | 2021-09-07 | 深圳绿养时代新技术有限公司 | Feed additive for improving DHA enrichment in eggs and preparation method thereof |
| CN114558099A (en) * | 2022-03-29 | 2022-05-31 | 沈阳市第六人民医院 | Traditional Chinese medicine composition and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266532A (en) * | 2011-07-27 | 2011-12-07 | 张秀兰 | Medicament for treating fatty liver and preparation method thereof |
-
2014
- 2014-06-30 CN CN201410303935.7A patent/CN104013926A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102266532A (en) * | 2011-07-27 | 2011-12-07 | 张秀兰 | Medicament for treating fatty liver and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 徐生生: ""护肝消脂饮"治疗脂肪肝45例临床观察", 《江苏中医药》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104274610A (en) * | 2014-10-30 | 2015-01-14 | 崔新明 | Traditional Chinese medicine composition for treating fatty liver |
| CN104491094A (en) * | 2014-12-19 | 2015-04-08 | 孙丰卿 | Traditional Chinese medicine composition for treating fatty liver and preparation method of preparation thereof |
| CN105797010A (en) * | 2014-12-29 | 2016-07-27 | 伊启棒（天津）科技发展有限公司 | Composition for improving fatty liver |
| CN104606641A (en) * | 2015-02-06 | 2015-05-13 | 刘延玲 | Traditional Chinese medicine for promoting fat metabolism and preparation method of traditional Chinese medicine |
| CN104888155A (en) * | 2015-07-04 | 2015-09-09 | 青岛辰达生物科技有限公司 | Traditional Chinese medicine composition for treating fatty liver combined hyperlipidemia and preparation method thereof |
| CN105535826A (en) * | 2015-12-29 | 2016-05-04 | 上海珍岛信息技术有限公司 | Pharmaceutical composition for treating cat fatty liver and preparation method thereof |
| CN113349311A (en) * | 2021-06-28 | 2021-09-07 | 深圳绿养时代新技术有限公司 | Feed additive for improving DHA enrichment in eggs and preparation method thereof |
| CN114558099A (en) * | 2022-03-29 | 2022-05-31 | 沈阳市第六人民医院 | Traditional Chinese medicine composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102727686B (en) | Traditional Chinese medicine composition for treating fatty liver | |
| CN104013926A (en) | Traditional Chinese medicine composition and application of traditional Chinese medicine composition as medicine for treating fatty liver | |
| CN103990081B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice | |
| CN104042802A (en) | Traditional Chinese medicine composition capable of treating fatty liver | |
| CN103301412A (en) | Traditional Chinese medicine composition for treating alcoholic liver | |
| CN103316249B (en) | Astragalus taxus chinensis capsule and preparing process thereof | |
| CN102389554B (en) | Chinese medicinal formula capable of invigorating kidney yang and tonifying kidney yin as well as its product | |
| CN104027568A (en) | Traditional Chinese medicine composition for treating climacteric syndrome and preparation method thereof | |
| CN103301267B (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN104984267A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN102247479A (en) | Antitumor strong medicine and preparation method thereof | |
| CN104043077A (en) | Traditional Chinese medicine composition for tonifying qi and nourishing blood | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN104771589A (en) | Traditional Chinese medicine composition for treating fatty liver and application thereof | |
| CN101757206A (en) | Chinese medicine preparation for treating chronic colitis | |
| CN103705731B (en) | A kind of Chinese medicine composition for the treatment of chronic alcoholic toxic liver disease | |
| CN103877483A (en) | Traditional Chinese medicine for treating chronic gastritis and preparation method thereof | |
| CN103495103B (en) | Medicament for promoting digestion and strengthening spleen | |
| CN103041233A (en) | Pharmaceutical composition for treating infantile diarrhea and preparation method thereof | |
| CN104666999A (en) | Traditional Chinese medicine formula capable of reducing blood pressure | |
| CN103721229A (en) | Traditional Chinese medicinal composition for treating infantile cough and asthma and preparation method thereof | |
| CN103285130B (en) | Chinese medicine composition for liver cancer treatment and preparing method thereof | |
| CN104825977A (en) | Traditional Chinese medicine composition for treating spleen deficiency food damage type postpartum food damage and preparation method of traditional Chinese medicine composition | |
| CN105381414A (en) | Traditional Chinese medicine preparation for treating breast lumps and cystic hyperplasia and preparation method thereof | |
| CN105497760A (en) | Fatty liver treating traditional Chinese medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140903 |